Engineered viruses are the delivery vehicle of choice for many genetic medicines, but they pose several problems. In addition to the risk of dangerous immune responses, these viruses don’t go to all ...
GREATER PHILADELPHIA, Pa.--(BUSINESS WIRE)--Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced its upsized and ...
Duchenne muscular dystrophy (DMD) and Type 1 diabetes couldn’t be more different: One is fairly rare and degenerative, while we hear about the other life-altering condition all the time. A new biotech ...
Biotechnology startup Code Biotherapeutics Inc. has raised $75 million in new venture capital to develop genetic medicines based on technology designed to make these types of treatments more widely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results